Poster Two is available here. The treatment period is still ambiguous. BETonMACE study design reads up to 104 weeks treatment. Results reads 6 to 36 months treatment. Nice baseline data on the n=259 CKD sub population.
BETonMACE Chronic Kidney Disease Sub-Study: Effects of the Selective BET-Inhibitor Apabetalone on Kidney Function and MACE in Post-ACS Patients with Diabetes and Estimated Glomerular Filtration Rate Below 60.